利福昔明胶囊对急性感染性腹泻的疗效和安全性及其血药浓度测定

目的评价利福昔明胶囊（抗结核病药）治疗急性感染性腹泻的疗效、安全性及口服后吸收情况。方法用随机对照前瞻性试验方法，共入选病例70例，利福昔明胶囊（试验组33例）每次200mg，每6h1次；左氧氟沙星胶囊（对照组35例）每次200mg，每12h1次，疗程均3天。试验组有10例患者接受了血药浓度分析。结果从开始服药至最后1次排不成型便的时间，试验组和对照组平均分别为33．56，31．13h，2组相比无明显差异（P〉0．05）；2者的临床疗效比较也无明显差异（P〉0．05）；利福昔明口服后血药浓度极低或测不出。结论利福昔明口服后基本不吸收，是治疗急性感染性腹泻的安全有效药物。

Effectiveness and safety of rifaximin capsule in the treatment of acute infectious diarrhea and determination its plasma concentration

Objective To eveluate the efficacy and safety of rifaximin capsule in the treatment of acute infectious diarrhea and determinate its plasma concentration of rifaximin after oral administration in patients. Methods It was a randomized,comparative,prospective clinical trial.The dosage of rifaximin (35 cases,trial) was 200 mg,q 6 h. The dosage of levofloxacin (33 cases,control) was 200 mg q12 h.The duration of treatment was 3 days in both groups.The total number of enrolled subjects was 70.Ten patients in trial group accepted analysis of plasma concentration after oral administraion. All patients were assessed efficacy and safety.Results The mean length of the time from initiation of therapy to passage of last unformed stool(TLUS)of rifaximin group was 33.56 h ,the other was 31.13 h. There was no significant difference between them(P>0.05).Final assessment of effectiveness of two drugs indicated that there was no significant difference between them(P>0.05).Conclusion Rifaximin was rarely absorbed after oral administration,it was a effective and safe drug in treating acute infectious diarrhea.